Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT-128800 dose-finding study in relapsing-remitting multiple sclerosis
2008-006786-92Phase 2Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Mar 2009
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ponesimod in relapsing-remitting multiple sclerosis (RRMS) (4 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Cumulative number of new gadolinium-enhancing lesions. Started Mar 2009; status: completed.
02
Drugs
ponesimod
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2008-006786-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006786-92.